Quantitative cytomegalovirus (CMV) monitoring is still far from being standardized between transplant centers. In the present study, we compared assays for quantitative CMV monitoring using blood cells and plasma. Four hundred and thirty-five consecutive samples from 29 patients with active CMV infection after allogeneic Tcell-depleted hemopoietic stem cell transplantation were tested in parallel using pp65 antigenemia and quantitative CMV polymerase chain reaction (PCR) in blood cells and plasma (COBAS AMPLICOR CMV MONITOR). Although only 142 (53.1%) of 253 positive samples were concordantly identified by all three assays, the number of positive samples detected by each assay was not different and the quantitative values were correlated, provided that nucleic acid (NA) in plasma was isolated by COBAS AmpliPrep and not by the manual protocol. Six (18%) of 34 episodes with active CMV infection were not detected using CMV PCR in plasma; whereas in times of white blood cell aplasia or blast crisis of leukemia, samples with active CMV infection in plasma could not be detected using blood cells. We conclude that CMV monitoring in whole blood could be favorable compared with assays using plasma or blood cells alone. Automated NA isolation could become an attractive tool for a more sensitive and better standardized molecular diagnostics.
Introduction
Cytomegalovirus (CMV) is an important opportunistic pathogen in patients after hemopoietic stem cell transplantation. 1 During the last decades, the improved diagnostic and therapeutic options resulted in a decreased CMVassociated morbidity and mortality. 2 An early and sensitive detection of active CMV infection can be achieved by various quantitative assays potentially offering an opportunity to predict the occurrence and outcome of CMV disease. Transplant patients with high and very dynamic increase of viral load have been shown to be predisposed for CMV disease, whereas most patients after stem cell transplantation with low-level CMV replication did not develop CMV disease even without antiviral therapy. 3, 4 Owing to the lack of interlaboratory standardization, the quantitative results of in-house assays cannot be compared between different transplant centers; however, a better comparability may be achieved by using standardized assays which are now commercially available. 5 Although diagnostic assays using blood cells are well established in most transplant centers, quantitative CMV polymerase chain reaction (PCR) in plasma is increasingly used for CMV monitoring. CMV monitoring in plasma might be easier to standardize and to perform compared with assays using isolated blood cells; [6] [7] [8] [9] however, generally the assays using plasma seemed to be less sensitive. 10 Automated nucleic acid (NA) isolation systems are now available and may contribute to a better standardized and more sensitive diagnosis of active CMV infection. 11 The present study was aimed at comparing CMV monitoring in blood cells and plasma investigating patients after T-cell-depleted hematopoietic stem cell transplantation. In most studies, the different assays for CMV monitoring were compared only with respect to sensitivities; however, the occurrence of CMV in blood cells or plasma may be different in various patients and in various clinical situations, and therefore one has to be careful not to compare 'apples with oranges' by measuring CMV in different blood compartments.
Materials and methods

Patients and samples
Over a period of 12 consecutive months, the patients with T-cell-depleted hemopoietic stem cell transplantation treated at the University Hospital, Ulm, Germany, were recorded and prospectively monitored in one to two weekly intervals for active CMV infection using quantitative pp65 antigenemia and quantitative CMV PCR (COBAS AMPLICOR CMV MONITOR; CMM) in plasma and blood cells. Only patients with active CMV infection were included to focus the most important samples for CMV monitoring. In the patients the episodes with active CMV infections were defined by the detection of CMV in at least two samples using pp65 antigenemia, CMM in blood cells and/or CMM in plasma. Samples with negative CMM in plasma after manual NA isolation but positive results in blood cells (pp65 antigenemia, CMM in blood cells) were re-investigated by CMM after automated NA isolation of plasma.
The patients were transplanted because of malignant diseases except for one patient with thalassemia major. CMV prophylaxis was performed for the first 3 months after transplantation using ganciclovir (Hoffmann-LaRoche, Grenzach, Germany) or foscavir (AstraZeneca, Wedel, Germany). The study was approved by the local ethics committee, was in accordance with the declaration of Helsinki and informed consent of the patients was obtained.
Quantitative pp65 antigenemia
Peripheral blood cells were isolated by dextran sedimentation using 5 ml ethylenediaminetetraacetic acid-blood. EDTA-blood was mixed with the twofold volume of 1% phosphate-buffered saline (PBS) dextran (Carl-Roth, Karlsruhe, Germany) followed by sedimentation at 371C (30 min). The white blood cells (WBCs) were collected, washed with PBS and the remaining erythrocytes were lysed using 2 ml erythrocyte-lysing buffer (0.15 M NH 4 Cl, 10 mM EDTA, 10 mM KHCO 3 , pH 7.4 at 41C). Duplicates of 5 Â 10 5 blood cells were placed onto glass slides, fixed with methanol/acetone (1:1), incubated with two monoclonal mouse anti-pp65-antibodies (20:1; Virion, Ru¨schli-kon, Switzerland and Argene Biosoft, Viva Diagnostika, Hu¨rth, Germany; 30 min at 371C), washed with PBS and incubated with the secondary fluorescein isothiocyanateconjugated goat anti-mouse antibody (diluted 1:100; Dianova, Hamburg, Germany; 30 min at 371C). Unbound antibodies were removed by washing with PBS and the positive cells were detected using immunofluorescence microscopy (IFA).
Manual NA isolation using blood cells WBC count was routinely determined by an automated system (Coulter, Fullerton, CA, USA). The blood cells were isolated by 1 ml EDTA-blood by incubation in erythrocyte-lysing buffer (0.15 M NH 4 Cl, 10 mM EDTA, 10 mM KHCO 3 , pH 7.4; 41C) and consecutive centrifugation (5 min at 200 g). NA isolation of the blood cells was performed according to the manufacturer's leukocyte protocol (COBAS AMPLICOR CMV MONITOR; Roche Diagnostics, Alameda, CA, USA). Of the 400 ml NA isolate, 50 ml was applied to the quantitative CMV PCR (CMM). The quantitative results were given as genome equivalents (GEs) per 10 6 blood cells.
Manual NA isolation using plasma Manual NA isolation was performed according to the manufacturer's instruction (COBAS AMPLICOR CMV MONITOR; Roche Diagnostics, Alameda, CA, USA) using 200 ml plasma. The NA extracts were diluted in 400 and 50 ml was analyzed by the quantitative CMV PCR (CMM).
Automated NA isolation in plasma using COBAS AmpliPrep Automated NA isolation in plasma was performed with COBAS AmpliPrep and Total Nucleic Acid Isolation kit (both from Roche Diagnostics, Mannheim, Germany). Then, 500 ml plasma was applied to the automated system. The NA extracts were dissolved in 65 ml, and 50 ml was analyzed by quantitative CMV PCR (CMM).
Quantitative CMV PCR by COBAS AMPLICOR CMV MONITOR
Quantitative CMV PCR by COBAS AMPLICOR CMV MONITOR (CMM; Roche Diagnostics, Alameda, CA, USA) was designed to co-amplify the N-terminal region of UL54 (CMV polymerase) and an internal standard. Automated amplification and quantitative detection were performed (COBAS AMPLICOR) and the quantitative values are given as GE/ml. The linear detection limit of CMM after manual NA isolation of plasma is specified at 400 GE/ml.
CMV shell vial culture
Shell vial culture using blood cells was performed with human embryonic lung fibroblast (HEL) as described earlier. 10 Briefly, blood cells were isolated by dextran sedimentation, sonified for 15 s at 70 W (Branson Sonifier; Danbury, CT, USA) and co-incubated with HEL. After 4 h, the medium was changed (minimal essential medium supplemented with 10% fetal calf serum, 1% penicillin/ streptomycin, 1% glutamine, 1% non-essential amino acids) and the cultures were incubated at 371C. Three days later, the cells were fixed with methanol/acetone (1:1) and CMV infection was detected by IFA using a cocktail of two monoclonal mouse antibodies (hybridoma supernatants of mouse anti-CMV IE1 and mouse anti-CMV UL69 antibodies).
Onset and end of active CMV infection
The initial and the last detection of pp65 antigenemia were defined as the zero point for onset and end of active CMV infection in the present study. This allowed us to compare the time course of active CMV infection detected by the various assays (Figure 1 ).
Statistical analysis
Non-parametric tests (Fischer's exact test, Mann-Whitney U test, McNemar test) and Pearson correlation test were analyzed using GraphPad Prism 3.02 software (GraphPad Software, San Diego, CA, USA), and statistical significance was set at a level of P ¼ 0.05.
Results
Patients and samples
Overall, 40 consecutive patients after T-cell-depleted allogeneic stem cell transplantation were monitored. Twentynine CMV seropositive patients with 34 episodes of active CMV infection were included. Of each patient, 8-31 consecutive samples were investigated. Thereby, a total number of 435 samples were evaluated in parallel using pp65 antigenemia, CMM in blood cells and CMM in plasma. In 253 samples, a positive result was found by at least one assay. Being aware of the lower sensitivity of this assay, CMV shell vial culture was routinely performed in each sample to detect infectious virus and to obtain CMV isolates for further characterization.
Qualitative results of pp65 antigenemia, CMM in plasma and CMM in blood cells Among the 253 samples with positive results, in at least one of the assays (100%), we found only 139 samples (54.9%) to be positive using CMM after manual NA isolation in plasma (data not shown). However, after performing automated NA isolation, 50 additional samples with low CMV-DNA copy numbers were also detected to be positive (median 126 GE/ml; range 33-510 GE/ml). Thus, we demonstrated that the percentage of positive results was significantly increased using automated vs manual NA isolation (54.9 vs 74.7%; Po0.001). Of the 253 samples with positive results, 209 (82.6%) were found to be positive using CMM in blood cells and 201 (79.5%) using pp65 antigenemia. We demonstrated that the percentage of positive samples was not significantly different using pp65 antigenemia, CMM in blood cells and CMM in plasma 
Episodes with active CMV infection
The 34 episodes with active CMV infection defined by at least two positive samples were all detected in the blood cell compartment using pp65 antigenemia (100%) and also CMM in blood cells (100%); however, only 28 episodes (82%; P ¼ 0.025) with active CMV infection were detected using CMM in plasma and only 24 episodes (71%; P ¼ 0.001) using shell vial culture, which was significantly lower than pp65 antigenemia and CMM in blood cells.
By investigation of blood cells (pp65 antigenemia, CMM in blood cells), the onset of active CMV infection was detected generally earlier or at the same time compared with CMM in plasma (Figure 1 ). However, in three patients various assays. The initial detection of CMV by pp65 antigenemia was defined as zero-point for the onset of active CMV infection, which allowed us to investigate the incidence of episodes with active CMV infection detected by various assays during the follow-up. Episodes with active CMV infection were equally detected by the assays in blood cells (pp65-antigenemia, CMM in blood cells) but the number of episodes was underestimated using CMM in plasma and shell vial culture. Differences between the initial detection of active CMV infection by the assays may occur due to sensitivity problems (e.g., shell vial culture) and also due to the different occurrence of CMV in the blood cell and the plasma compartment. with WBC aplasia after myeloablative chemotherapy the detection of active CMV infection was achieved earlier in the plasma compartment. The detection of active CMV infection using shell vial culture was generally delayed (median 10 days, range 0-49 days; P ¼ 0.038), which has been extensively shown in various previous studies.
Episodes with predominantly cell-associated CMV infection
The six episodes (five patients) with negative CMM in plasma were characterized by a shorter duration (17.574. 0 vs 80.5711.1 days; P ¼ 0.0003) and a lower viral load (3.871.6 vs 211.7786.4 pp65-antigen-positive/ 5 Â 10 5 blood cells; P ¼ 0.028) than the 28 episodes (24 patients) with positive CMM in plasma. None of these patients developed CMV pneumonitis or other severe CMV-associated diseases.
Discussion
Early detection of CMV by sensitive quantitative assays is the basis for CMV monitoring after hemopoietic stem cell transplantation. 5 Although CMV shell vial culture is no longer recommended for CMV monitoring and subsequent preemptive antiviral therapy, 12 the cell culture is routinely performed in our laboratory to show infectivity and to obtain patients isolates for further characterization. Thereby, we again confirmed the lower sensitivity and delayed detection of active CMV infection using CMV shell vial culture; however, this was not the focus of the present study.
To date, very sensitive quantitative assays in blood cells are established for CMV monitoring in most transplant centers (e.g., pp65 antigenemia, CMV PCR); however, assays in plasma are supposed to be less time consuming, easier to perform and better to standardize. In the literature, CMV detection in plasma is mostly less sensitive than the assays in blood cells; 10 however, more sensitive inhouse CMV PCR assays in plasma were recently established 9,13 and automated NA isolation could also provide a more sensitive diagnosis of active CMV infection. 11 In our study, the sensitivity of CMM in plasma was significantly increased using automated NA isolation with COBAS AmpliPrep and Total Nucleic Acid Isolation kit than the standard manual NA isolation. Presumably, the sensitivity was mainly increased owing to an increased sample volume (500 vs 200 ml) and a reduced diluent volume (65 vs 400 ml). Thereby, the quantity of putative input virus per PCR was enhanced by the factor of 15 and the sensitivity of CMV PCR was increased. Purer NA extracts and a better depletion of PCR inhibitors by the automated NA isolation could additionally improve the PCR performance. As automated NA isolation increases the sensitivity of quantitative CMV PCR in plasma, we assume that automation could also improve the sensitivity of molecular diagnostic assays of other pathogens although that still remains to be shown.
Although only 142 (56.1%) of 253 samples with positive results in at least one assay were detected concordantly positive by pp65 antigenemia, CMM in blood cells and CMM in plasma, the percentage of positive samples detected by each assay was not significantly different (Figure 2 ), provided that automated and not manual NA isolation was performed in plasma. The overall comparability of the assays was also shown for the quantitative values, which were significantly correlated as was also shown in a previous study.
14 However, discrepancies between the assays were also found, which could have occurred due to sampling error or principal differences between the assays.
Principal differences between assays were shown here for the assays using blood cells or plasma. On the one hand, we demonstrated that 18% of episodes with active CMV infection were not detected in the plasma compartment but in blood cells, which would be fatal if the active CMV infections were clinically relevant in this patient group. However, in the present study the episodes with exclusively cell-associated CMV infection were characterized by a shorter course and a lower viral load in the blood cell compartment. Being aware of the limited number of patients we speculate that the absence of severe CMV disease in patients with exclusively cell-associated CMV infection may indicate a lower predisposition for CMV disease. One might also speculate that viral spread from the blood cell compartment to the plasma compartment could be prevented in this patient group by a more active antiviral immune response; however, this assumption remains to be proven in prospective studies.
On the other hand, we demonstrated in three patients that active CMV infection was not detected in the blood cell compartment before WBC reconstitution (three patients). 6, 15 Also, during blast crisis of leukemia (one patient) active CMV infection could not be identified in blood cells. WBC aplasia after myeloablative radiochemotherapy generally occurs during the first weeks after hemopoietic stem cell transplantation. Therefore, the detection of early onset CMV infection and its preemptive therapy may be delayed when using CMV monitoring in blood cells alone. False negative results in blood cells during blast crisis of leukemia could be explained by the predominance of CMV non-permissive blast cells in the samples.
Despite a vast comparability of the assays, we assume that there are also principle differences of CMV detection in blood cells and plasma that may limit the detection of CMV in blood cells or plasma alone. Therefore, we suggest that CMV monitoring in whole blood could be superior to assays in blood cells or plasma alone; however, this remains to be virologically and clinically evaluated in future studies. Automated NA isolation could generally become an attractive tool for more sensitive and better standardized molecular diagnostics of active CMV infection and presumably also of other pathogens.
